Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature

This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vortioxetine for treating MDD in adults is supported by eight positive short-term (6- to 12-weeks) randomized, placebo-controlled trials, and one positive randomized, double-blind, 52-week relapse prevention trial. Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning. Vortioxetine also appears to be effective for treating symptoms of MDD in the elderly based on the results of one randomized trial for which recruitment was focused on this specific population. Nevertheless, effectiveness studies that directly compare the clinical effects of vortioxetine with other established antidepressant drugs are lacking, and there is no evidence as yet that vortioxetine is more clinically effective than other types of antidepressants. Some preliminary suggestions concerning the place of vortioxetine among the broad range of pharmacological treatments for adults with MDD are provided.

• Publication year

  2015

• Venue

  Therapeutics and Clinical Risk Management

• Publication date

  2015-08-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/TCRM.S55313PMID 26316764PMCID 4542474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.

  2015influential reference
• Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.

  2015influential reference
• A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.

  2015cited by this paper
• Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.

  2015influential reference
• Mechanism of action of antidepressants.

  2015cited by this paper
• The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.

  2015cited by this paper
• Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies

  2014influential reference
• Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

  2014influential reference
• Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder

  2014cited by this paper
• The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis

  2014cited by this paper
• A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine

  2014influential reference
• Vortioxetine for the Treatment of Depression

  2014cited by this paper
• Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials

  2014influential reference
• A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

  2014cited by this paper
• Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder

  2014cited by this paper
• A randomized, double‐blind, fixed‐dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder

  2014cited by this paper
• Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

  2013cited by this paper
• A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

  2013cited by this paper
• Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant

  2013cited by this paper
• A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.

  2013cited by this paper
• Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010

  2013cited by this paper
• Serotonin and beyond: therapeutics for major depression

  2013cited by this paper
• Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.

  2013cited by this paper
• Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis

  2013cited by this paper
• DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, FIFTH EDITION

  2013cited by this paper
• 50 years of hurdles and hope in anxiolytic drug discovery

  2013cited by this paper
• A Randomized Trial on the Acute and Steady‐State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition

  2013cited by this paper
• Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

  2013cited by this paper
• A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder

  2012cited by this paper
• Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

  2012cited by this paper
• A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

  2012cited by this paper
• A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).

  2012cited by this paper
• On assessing potential efficacy for vortioxetine in generalized anxiety disorder.

  2012cited by this paper
• Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.

  2012cited by this paper
• Identification of the Cytochrome P450 and Other Enzymes Involved in the In Vitro Oxidative Metabolism of a Novel Antidepressant, Lu AA21004

  2012cited by this paper
• Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects.

  2012cited by this paper
• Translational Evaluation of JNJ-18038683, a 5-Hydroxytryptamine Type 7 Receptor Antagonist, on Rapid Eye Movement Sleep and in Major Depressive Disorder

  2012cited by this paper
• Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

  2012cited by this paper
• Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.

  2012cited by this paper
• A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

  2012influential reference
• Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.

  2011cited by this paper
• Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

  2011influential reference
• A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

  2011influential reference
• The role of serotonin receptor subtypes in treating depression: a review of animal studies

  2011cited by this paper
• The natural course and outcome of major depressive disorder in primary care: the PREDICT-NL study

  2010cited by this paper
• When should you move beyond first-line therapy for depression?

  2010cited by this paper
• Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.

  2009cited by this paper
• Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

  2009cited by this paper
• Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods

  2009cited by this paper
• Vilazodone: A 5‐HT1A Receptor Agonist/Serotonin Transporter Inhibitor for the Treatment of Affective Disorders

  2009cited by this paper
• Population-based study of first onset and chronicity in major depressive disorder.

  2008cited by this paper
• The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach.

  2008cited by this paper
• Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.

  2007cited by this paper
• Serotonergic vulnerability and depression: assumptions, experimental evidence and implications

  2007cited by this paper
• Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.

  2007cited by this paper
• Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.

  2007cited by this paper
• Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up

  2007cited by this paper
• Depression

  2007cited by this paper
• What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials.

  2007cited by this paper
• Medical management of depression.

  2006cited by this paper
• Antidepressant discontinuation syndrome.

  2006cited by this paper
• Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

  2006cited by this paper
• Pindolol augmentation of antidepressant response.

  2006cited by this paper
• Medication augmentation after the failure of SSRIs for depression.

  2006cited by this paper
• Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials

  2006cited by this paper
• Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey.

  2006cited by this paper
• Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

  2006cited by this paper
• Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial.

  2005cited by this paper
• Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions.

  2005influential reference
• The medical management of depression.

  2005cited by this paper
• Depression: management of depression in primary and secondary care

  2005cited by this paper
• Central monoamines and their role in major depression.

  2004influential reference
• Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.

  2004cited by this paper
• The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig.

  2004cited by this paper
• Promoting Mental Health: Concepts, Emerging Evidence, Practice - Summary Report

  2004cited by this paper
• A Survey of Sexual Side Effects Among Severely Mentally Ill Patients Taking Psychotropic Medications: Impact on Compliance

  2003cited by this paper
• Is there a role for 5-HT1A agonists in the treatment of depression?

  2003cited by this paper
• Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance.

  2003cited by this paper
• Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond.

  2003cited by this paper
• Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.

  2000cited by this paper
• The Arizona Sexual Experience Scale (ASEX): reliability and validity.

  2000cited by this paper
• Treatment options for refractory depression.

  1999cited by this paper
• The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial.

  1999cited by this paper
• Suicide risk in patients with major depressive disorder.

  1999cited by this paper
• A double-blind, randomized, placebo-controlled trial of Pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors

  1999cited by this paper
• A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.

  1999cited by this paper
• Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

  1998cited by this paper
• Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects.

  1998cited by this paper
• Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial.

  1997cited by this paper
• Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.

  1997cited by this paper
• When at first you don't succeed: sequential strategies for antidepressant nonresponders.

  1997cited by this paper
• The Time Course of Nonchronic Major Depressive Disorder: Uniformity Across Episodes and Samples

  1994cited by this paper
• The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression--Clinical Studies.

  1994cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• The catecholamine hypothesis of affective disorders: a review of supporting evidence.

  1965cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper
• Clinical Ophthalmology Dovepress

  year unknowncited by this paper
• PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Evaluation of patients ’ experiences with antidepressants reported by means of a medicine reporting system

  year unknowncited by this paper

• Effectiveness of Vortioxetine in Relieving Chronic Pain in Patients with Associated Depression in a Spanish Population

  2025influential citation
• Maternal Use of Antidepressants in Pregnancy and the Risk of Postpartum Hemorrhage: An Electronic Health Record‐Based Cohort Study

  2025cites this paper
• Individualized strategies for depression: narrative review of clinical profiles responsive to vortioxetine

  2024cites this paper
• Effectiveness of Vortioxetine in Patients with Major Depressive Disorder Associated with Chronic Pain: An Observational Study in a Spanish Population

  2024influential citation
• Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial

  2024cites this paper
• Switching to Vortioxetine in Patients with Poorly Tolerated Antidepressant-Related Sexual Dysfunction in Clinical Practice: A 3-Month Prospective Real-Life Study

  2024cites this paper
• Analytically Confirmed Intentional Overdose of the Antidepressant Vortioxetine

  2024cites this paper
• Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism—In Vitro Study

  2022cites this paper
• Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study

  2022cites this paper
• BURNING MOUTH DISEASE, MODERN TREATMENT AND CLINICAL MANAGEMENT: A NARRATIVE REVIEW

  2022cites this paper
• Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor

  2021cites this paper
• 5-HT Receptors and the Development of New Antidepressants

  2021cites this paper
• Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.

  2020cites this paper
• A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder

  2020cites this paper
• An updated classification of antidepressants: A proposal to simplify treatment

  2020cites this paper
• Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT1A Receptor with 5-HT3 Receptor Inhibition in Rats

  2019cites this paper
• Assessment of Oral Health-related Quality of Life, measured by OHIP-14 and GOHAI, and psychological profiling in Burning Mouth Syndrome: a case-control clinical study.

  2019cites this paper
• Vortioxetine in the Treatment of Mood Disorders Associated with Burning Mouth Syndrome: Results of an Open-Label, Flexible-Dose Pilot Study.

  2019cites this paper
• Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial

  2019cites this paper
• Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety

  2018cites this paper
• The Overlapping Thermodynamic Dissociation Constants of the Antidepressant Vortioxetine Using UV–VIS Multiwavelength pH-Titration Data

  2018cites this paper
• Vortioxetine: A new alternative for the treatment of major depressive disorder

  2018cites this paper
• Chapter 7 New Antidepressant Medication : Benefits Versus Adverse Effects

  2018influential citation
• Serotonin receptors in depression and anxiety: Insights from animal studies

  2018cites this paper
• Efficacy of vortioxetine on the physical symptoms of major depressive disorder

  2018influential citation
• Vortioxetine: A new alternative for the treatment of major depressive disorder.

  2017cites this paper
• Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.

  2017cites this paper
• New Antidepressant Medication: Benefits Versus Adverse Effects

  2017influential citation
• Depression in older adults: Diagnosis and management

  2017cites this paper
• VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES.

  2016cites this paper
• Wortioksetyna – lek przeciwdepresyjny o wielofunkcyjnym mechanizmie działania

  2016cites this paper
• [Vortioxetine in the treatment of major depression].

  2016cites this paper